Holen Sie sich die Stockscreener-App
50.00
3.14%
1.52
Handel nachbörslich:
49.87
-0.13
-0.26%
Schlusskurs vom Vortag:
$48.48
Offen:
$48.6
24-Stunden-Volumen:
3.04M
Relative Volume:
0.86
Marktkapitalisierung:
$22.22B
Einnahmen:
$2.38B
Nettoeinkommen (Verlust:
$1.32B
KGV:
28.08
EPS:
1.7806
Netto-Cashflow:
$897.24M
1W Leistung:
+4.38%
1M Leistung:
+8.44%
6M Leistung:
+35.10%
1J Leistung:
+53.37%
1-Tages-Spanne:
$48.35
$50.00
1-Wochen-Bereich:
$47.81
$50.00
52-Wochen-Spanne:
$31.58
$50.00
Royalty Pharma Plc Stock (RPRX) Company Profile
Firmenname
Royalty Pharma Plc
Sektor
Branche
Telefon
(212) 883-0200
Adresse
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
50.00 | 22.22B | 2.38B | 1.32B | 897.24M | 1.7806 |
VRTX
Vertex Pharmaceuticals Inc
|
441.20 | 112.22B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
750.57 | 79.35B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
849.04 | 52.80B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
309.66 | 41.32B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
323.87 | 35.95B | 5.36B | 287.73M | 924.18M | 2.5229 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-30 | Hochstufung | UBS | Neutral → Buy |
| 2025-09-30 | Eingeleitet | Goldman | Buy |
| 2025-05-16 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-06-03 | Herabstufung | UBS | Buy → Neutral |
| 2022-06-14 | Fortgesetzt | UBS | Buy |
| 2022-05-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-04-27 | Eingeleitet | Goldman | Buy |
| 2022-04-14 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-10-29 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-07-30 | Eingeleitet | Tigress Financial | Buy |
| 2020-11-09 | Hochstufung | UBS | Neutral → Buy |
| 2020-07-14 | Eingeleitet | Evercore ISI | In-line |
| 2020-07-13 | Eingeleitet | BofA Securities | Buy |
| 2020-07-13 | Eingeleitet | Citigroup | Neutral |
| 2020-07-13 | Eingeleitet | Cowen | Outperform |
| 2020-07-13 | Eingeleitet | Goldman | Neutral |
| 2020-07-13 | Eingeleitet | JP Morgan | Neutral |
| 2020-07-13 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-07-13 | Eingeleitet | SunTrust | Buy |
| 2020-07-13 | Eingeleitet | UBS | Neutral |
Alle ansehen
Royalty Pharma Plc Aktie (RPRX) Neueste Nachrichten
Moran Wealth Management LLC Grows Position in Royalty Pharma PLC $RPRX - MarketBeat
KBC Group NV Trims Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma declares $0.235 dividend - MSN
5 Most Undervalued Biotech Stocks to Buy Right Now - Insider Monkey
Royalty Pharma PLC (NASDAQ:RPRX) Declares $0.24 Quarterly Dividend - MarketBeat
Royalty Pharma (NASDAQ:RPRX) Hits New 1-Year HighShould You Buy? - MarketBeat
Royalty Pharma stock hits 52-week high at $49.07 By Investing.com - Investing.com Canada
Royalty Pharma declares $0.235 quarterly dividend By Investing.com - Investing.com South Africa
Royalty Pharma plc Declares Dividend for the Second Quarter 2026, Payable on June 10, 2026 - marketscreener.com
Royalty Pharma declares $0.235 quarterly dividend - Investing.com
Royalty Pharma Keeps Quarterly Dividend at $0.235 per Share, Payable June 10 to Shareholders of Record as of May 15 - marketscreener.com
Royalty Pharma Declares Second Quarter 2026 Dividend - The Manila Times
Royalty Pharma plc (RPRX) Declares $0.235 Quarterly Dividend; 1.9% Yield - StreetInsider
Royalty Pharma will pay shareholders 23.5 cents a share on June 10 - Stock Titan
Royalty Pharma signs $500M co-development agreement with J&J - MSN
Sumitomo Mitsui Trust Group Inc. Acquires 166,403 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma to Announce Q1 2026 Results on May 6 - National Today
TD Cowen lifts PT on Royalty Pharma plc (RPRX) to $50 from $45, here’s why - MSN
Royalty Pharma : Q1 2026 Pre-Quarterly Results Communication - marketscreener.com
Royalty Pharma to Announce First Quarter 2026 Financial Results on May 6, 2026 - The Manila Times
Royalty Pharma schedules May 6 results, 8 a.m. investor webcast - Stock Titan
Foster Victor Wealth Advisors LLC Takes Position in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma : 2025 Corporate Responsibility Report pdf - marketscreener.com
Can Royalty Pharma (RPRX) Keep the Earnings Surprise Streak Alive? - Yahoo Finance
Robeco Institutional Asset Management B.V. Decreases Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma plc 8-K Filing – April 2026 Company Information and SEC Disclosure - Minichart
Royalty Pharma funds additional $250M after Phase 3 win for daraxonrasib in metastatic PDAC - TradingView
Royalty Pharma (NASDAQ: RPRX) deepens $2B daraxonrasib royalty and loan pact - Stock Titan
Royalty Pharma plc (RPRX) Proved Resilience in Q1 by Gaining 25.6% - Insider Monkey
Baillie Gifford & Co. Sells 363,734 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Technical Reactions to RPRX Trends in Macro Strategies - Stock Traders Daily
Trend Review: Does Royalty Pharma plc have high return on assetsForecast Cut & Fast Exit and Entry Trade Guides - baoquankhu1.vn
[ARS] Royalty Pharma plc SEC Filing - Stock Titan
[DEF 14A] Royalty Pharma plc Definitive Proxy Statement - Stock Titan
Today's Analyst Rating Update for Royalty Pharma (RPRX) | RPRX S - GuruFocus
RPRX Stock Price, Quote & Chart | ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX) - ChartMill
Assessing Royalty Pharma (RPRX) Valuation After Johnson & Johnson Autoimmune Co Funding Deal - Sahm
Royalty Pharma plc (RPRX) stock price, news, quote and history - Yahoo Finance UK
Does J&J Co-Funding Deal Around Dual-Pathway Autoimmune Candidate Recast The Bull Case For Royalty Pharma (RPRX)? - Sahm
Branded Pharmaceuticals Stocks Q4 Teardown: Royalty Pharma (NASDAQ:RPRX) Vs The Rest - Barchart
Volume Summary: Can Royalty Pharma plc scale operations efficiently2026 Highlights & Capital Protection Trading Alerts - baoquankhu1.vn
Aberdeen Group plc Acquires 98,191 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Can Royalty Pharma plc deliver consistent dividends2026 Outlook & Breakout Confirmation Trade Signals - baoquankhu1.vn
RPRX Financials: Revenue Breakdown, Margins & Competitor Comparison - intellectia.ai
RPRX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Royalty Pharma Leans Into R&D And AI To Shape Future Royalties - Sahm
Royalty Pharma Plc Hits New 52-Week High at $48.74 - Markets Mojo
Royalty Pharma (NASDAQ:RPRX) CFO Terrance Coyne Sells 34,791 Shares - marketbeat.com
Royalty Pharma (RPRX) CFO-linked entities execute planned share sales - Stock Titan
Royalty Pharma plc (RPRX) latest stock news and headlines - Yahoo Finance Singapore
Royalty Pharma, Johnson & Johnson Strike $500M Autoimmune Drug Deal - Yahoo Finance UK
Finanzdaten der Royalty Pharma Plc-Aktie (RPRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.19%
0.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):